Numerous lines of preclinical and clinical evidence support the existence of a graft-versus-leukemia effect, but less evidence supporting a comparable graft-versus-lymphoma effect exists. We review here current clinical data addressing the graft-versus-lymphoma effect, including comparisons of autologous, syngeneic, and allogeneic transplantation; responses to immunomodulation; and responses to nonmyeloablative stem cell transplantation. Despite several limitations of the data, we believe that there is sufficient evidence suggesting a significant graftversus-lymphoma effect. In addition, we discuss approaches for clinical management of lymphoma patients, opportunities for mechanistic studies afforded by donor leukocyte infusions and nonmyeloablative transplantation, and suggestions for clinical studies to further define the magnitude and applicability of the graft-versus-lymphoma effect. For over two decades, scientists and clinicians have recognized the existence of a graft-versus-tumor effect, whose role has become increasingly important in the treatment of hematologic malignancies. Initially suggested by numerous animal studies and corroborated by considerable retrospective analysis of clinical data, this effect is most directly supported by durable responses to withdrawal of immunosuppression, administration of donor leukocytes, and more recently, nonmyeloablative stem cell transplantation. Most studies to date have investigated the graft-versusleukemia effect, while comparable studies of a graft-versuslymphoma effect have been limited. Current data regarding graft-versus-lymphoma activity, however, have increasingly supported the likelihood of its existence. We review below the most recent evidence, composed of case reports and small series, larger retrospective analyses, and few prospective studies, suggesting a graft-versus-lymphoma effect.
For over two decades, scientists and clinicians have recognized the existence of a graft-versus-tumor effect, whose role has become increasingly important in the treatment of hematologic malignancies. Initially suggested by numerous animal studies and corroborated by considerable retrospective analysis of clinical data, this effect is most directly supported by durable responses to withdrawal of immunosuppression, administration of donor leukocytes, and more recently, nonmyeloablative stem cell transplantation. Most studies to date have investigated the graft-versusleukemia effect, while comparable studies of a graft-versuslymphoma effect have been limited. Current data regarding graft-versus-lymphoma activity, however, have increasingly supported the likelihood of its existence. We review below the most recent evidence, composed of case reports and small series, larger retrospective analyses, and few prospective studies, suggesting a graft-versus-lymphoma effect.
Background
The antitumor capacity of allogeneic immune cells was first demonstrated by the experiments of Barnes et al, 1 in which leukemic mice were irradiated and rescued by allogeneic or syngeneic bone marrow. In this classic study, allogeneic transplantation conferred a lower relapse risk than syngeneic transplantation, a result recapitulated in a number of murine and canine models. [2] [3] [4] In the 1970s and 1980s, growing laboratory data were complemented by clinical observations suggesting graft-versus-tumor activity following human allogeneic transplantation in patients with leukemia. 5 Specifically, lower relapse rates were observed in recipients of allogeneic rather than syngeneic transplantation, 6 lower relapse rates were observed in allograft recipients who developed graft-versus-host disease (GVHD) than in those who did not, 7, 8 and increased relapse rates were observed following T-cell depletion of the donor graft. 9 Horowitz et al 10 confirmed these findings in a large analysis of International Bone Marrow Transplant Registry (IBMTR) data.
Clinicians appreciative of this graft-versus-tumor activity attempted to harness it by withdrawing immunosuppression and administering donor leukocyte infusions (DLIs) to patients with recurrent or persistent disease following transplantation. 11, 12 Complete responses in a significant percentage of patients led to broad application of this approach, [13] [14] [15] [16] which has enjoyed its greatest success in the treatment of chronic myelogenous leukemia (CML), where durable responses in chronic phase relapse are approximately 75%. [17] [18] [19] [20] [21] [22] Donor leukocyte infusions have also been utilized, with varying degrees of success, in the treatment of acute lymphocytic leukemia, 23 acute myelogenous leukemia and myelodysplasia, 24 myelofibrosis, 25, 26 and multiple myeloma. [27] [28] [29] The success of DLI in the treatment of leukemia demonstrates the therapeutic benefit of interactions between donor-derived leukocytes and host tumor cells. Indeed, the elimination of tumor cells by adoptive therapy has resulted in a strategy that both exploits the antitumor capacity of allogeneic cells and reduces the toxicities of conventional transplantation. [30] [31] [32] In such nonmyeloablative transplants, patients receive relatively nontoxic preparative regimens that are immunosuppressive enough to allow engraftment of the donor cells that ultimately effect antitumor activity. 33, 34 Long-lasting remissions have been observed in a variety of hematologic malignancies treated by this approach. 35, 36 Thus, clinical data supporting a graftversus-leukemia effect have included reduced relapse rates following allogeneic vs autologous transplantation and responses to immunomodulation and nonmyeloablative transplantation. We examined the literature for similar lines of evidence supporting a comparable graft-versuslymphoma effect.
Comparison of autologous, syngeneic, and allogeneic transplantation
Retrospective analyses consistently demonstrate significantly lower relapse rates for lymphoma patients receiving allogeneic rather than autologous transplantation; however, the higher treatment-related mortality characteristic of the former tempers this advantage, yielding similar overall survivals for the two strategies (see Table 1 ). The existence of a graft-versus-lymphoma effect was first suggested by Jones et al 37 in a series of 118 consecutive patients with non-Hodgkin's lymphoma and Hodgkin's disease (HD). An outcomes assessment of 38 allograft recipients and 80 autograft recipients showed a significantly lower relapse rate among allograft recipients, although a statistically significant difference in event-free survival between the two groups was not appreciated given the higher treatment-related mortality associated with allogeneic transplantation. A prospective study published 3 years later analyzed the outcomes of 66 consecutive patients with poor prognosis lymphoma, with priority for allogeneic transplantation given to patients younger than 55 years with a major histocompatibility complex-matched or one-antigen-disparate sibling donor. 38 Univariate analysis of the data suggested that the probability of disease progression remained significantly lower among allograft recipients, although, as in the Jones study, a statistically significant difference in progression-free survival was not apparent.
An analysis of 429 bone marrow transplants for nonHodgkin's lymphoma between 1986 and 1997 in Ontario yielded similar results. 39 In this retrospective study, 385 patients received autologous transplants, while 44 patients received allogeneic transplants for persistent marrow involvement or inadequate stem cell harvest. Allogeneic transplantation was associated with a significantly lower risk of relapse at 3 years (6 vs 41%, P ¼ 0.0006). The disparate group sizes and heterogeneity of the cohort were addressed by randomly matching two autologous transplant recipients to one allogeneic transplant recipient in terms of age, disease status at transplant, disease histology, and year of transplant. In this matched comparison, survival was equivalent between the two groups, but the relative risk for relapse after allogeneic transplantation was 0.190, corroborating the results of preceding studies. 40, 41 Studies focusing on single lymphoma histologies, such as lymphoblastic lymphoma, produce similar findings. Although recipients of allogeneic transplantation had a significantly lower 5-year relapse rate than recipients of autologous transplantation (34 vs 56%, P ¼ 0.004), higher treatment-related mortality offset any potential survival benefit. 42 The lower relapse rate for allogeneic transplant recipients held true after adjusting for the possible confounding effects of age, sex, Karnofsky score at the time of transplantation, disease stage at transplantation, bone marrow involvement at the time of transplantation, and several other factors.
Principle drawbacks to this group of studies include lack of randomization and the potential for selection bias (see Table 2 ). It has also been suggested that the higher relapse rates associated with autologous transplantation result from failure to purge the graft of tumor cells prior to infusion. van Besien et al 43 addressed this hypothesis by analyzing data collected from 904 patients with follicular lymphoma undergoing allogeneic (n ¼ 176), purged autologous (n ¼ 131), and unpurged autologous (n ¼ 597) transplantation between 1990 and 1999. In all, 5-year recurrence rates were 21, 43, and 58% after allotransplantation, purged autotransplantation, and unpurged autotransplantation, respectively, indicating a benefit to stem cell purging. As demonstrated previously, allogeneic transplantation conferred the lowest risk of relapse and the highest treatment-related mortality, resulting in a similar 5-year overall survival rate to autologous transplantation.
Perhaps the most provocative study to date comparing transplantation outcomes in patients with non-Hodgkin's lymphoma was published by the Lymphoma Working Committee of the IBMTR and the European Group for Blood and Bone Marrow Transplantation. 44 In this retrospective analysis of 3376 patients receiving syngeneic, autologous (with or without purging), or allogeneic (with or without T-cell depletion) transplantation, no significant difference in relapse rate was observed between syngeneic and allogeneic transplantation for any disease histology. Patients receiving unpurged autografts for low-grade disease had a five-fold greater risk of relapse than recipients of syngeneic transplants and a two-fold greater risk than recipients of purged autografts. Among patients with intermediate-or high-grade disease, however, there was no significant difference in relapse risk between purged and unpurged autologous transplants. According to the authors, these results failed to demonstrate a graft-versuslymphoma effect but suggested reinfusion of tumor cells as the cause of increased relapse rates in recipients of autologous transplants with low-grade disease.
These conclusions must be interpreted cautiously, however, given several drawbacks to the study design and data analysis. Importantly, the marked heterogeneity of the patient groups relative to histology and specific disease characteristics suggests that the difference in treatment outcome more likely resulted from differences in patient characteristics rather than the source of stem cells. For example, greater than 70% of patients undergoing autologous transplantation had chemosensitive disease, while this was true for fewer than 40% of allogeneic transplant recipients. 45 Of the allogeneic transplant recipients, 50% had high-grade histology compared with only 30% of syngeneic and 10% of autologous transplant recipients, and bone marrow involvement was present in 70% of allogeneic transplant recipients, but only 36% of syngeneic and 10% of autologous transplant recipients. These differences are consistent with general clinical experience: allografts are typically held in reserve until other treatments have failed, whereas syngeneic and autologous transplants, given their comparatively lower toxicity, are more likely to be used earlier in the disease course. This stands in marked contrast to the classic graftversus-leukemia analysis on which the design of this study is partially based, where patient populations were relatively homogeneous, with all acute leukemia patients in first remission and all CML patients in chronic phase. 10 Of course, the difference in lymphoma relapse rates with varying types of transplantation can only be answered by a properly designed prospective controlled trial, and such a trial is not likely to be carried out. 46 Such evidence has been limited largely to brief, yet compelling, case reports and small series. Aoyama et al 47 , for example, present the case of a 33-year-old Japanese man diagnosed with diffuse large B-cell lymphoma, stage IV, with invasion of the central nervous system. The patient was initially treated with aggressive chemotherapy, but nevertheless failed two autologous transplants and relapsed only 16 days following a nonmyeloablative allogeneic transplant. Cyclosporine A was discontinued on day þ 32, and a DLI was given on day þ 40. At 8 days after DLI, the patient developed grade III acute GVHD involving the skin and liver, and on day þ 220, the patient developed biopsy-proven chronic GVHD of the liver and lung. At 4 months after DLI, there was neither symptomatic nor radiological evidence of tumor, and at the time of publication, 15 months post transplant, the patient remained free of lymphoma and in good clinical condition.
Similarly, Mandigers et al 48 used real-time quantitative PCR with primers flanking the characteristic chromosomal translocation of follicular lymphoma to quantify objectively the graft-versus-lymphoma effect. The patient studied was a 48-year-old female with a low-grade follicular lymphoma who, after failing two previous treatment regimens, was given a high-dose preparative regimen and a T-cell-depleted allogeneic transplant. At 22 months following transplant, a relapse involving the lymph nodes and bone marrow was diagnosed. A single infusion of lymphocytes from the original donor resulted in durable complete remission, including a lymphoma-negative bone marrow, as measured by PCR. Table 3 lists several other examples of a graftversus-lymphoma effect mediated by the withdrawal of immunosuppression or the administration of DLI. These techniques have been effective against numerous lymphoma histologies, and in some cases, have resulted in durable remissions lasting over 7 years. The table also suggests the frequency with which acute and chronic GVHD occur in the setting of responders, although the correlation between these two variables is often not explicitly presented in the literature. Nevertheless, as in a previous analysis, 20 a strong temporal association between the development of GVHD and the induction of disease response appears to exist.
Despite the compelling nature of these reports, there are often confounding explanations for disease response (see Table 2 ). First, the administration of DLI is frequently preceded or accompanied by other agents with activity against lymphoma, including chemotherapy, radiation, and rituximab. 49 Secondly, corticosteroids used to treat GVHD accompanying DLI administration may also possess antilymphoma activity. Nevertheless, durable responses in often heavily pretreated and refractory patients are unlikely to be explained by these agents.
Response to nonmyeloablative stem cell transplantation

Limitations of the current literature
Numerous series have reported promising response rates to nonmyeloablative transplantation in patients with lymphoma. The current literature is limited, however, by the heterogeneity of nonmyeloablative transplantation regimens and the patients who receive them, the relatively limited reporting and short follow-up characteristic of most studies, and the current lack of randomized trials (see Table 2 ).
Approaches to nonmyeloablative transplantation vary significantly from study to study. Fludarabine-based regimens, often in combination with other chemotherapies and post transplantation immunosuppression, may differ considerably in intensity, but are generally well-tolerated and consistently result in engraftment. [50] [51] [52] Conditioning with fludarabine and melphalan, for example, frequently results in full donor chimerism and a risk of GVHD comparable to traditional myeloablative regimens, while conditioning with fludarabine and low-dose cyclophosphamide is more often associated with mixed chimerism and a comparatively low incidence of GVHD. Low-dose total body irradiation in various doses, either alone or in combination with immunosuppressive chemotherapy, has also emerged as an effective strategy for nonmyeloablative transplantation. 53 Selected patients receive DLI for persistent disease, mixed chimerism, or relapse after transplantation, but the precise criteria for DLI administration are not always clear, and if criteria are present, the degree of compliance is not always certain.
Cohorts in these studies are typically composed of patients with significant differences in baseline pretransplantation characteristics, including age, previous chemotherapies, chemosensitivity of disease, status at the time of transplantation, and donor type/degree of compatibility. Many registry analyses and retrospective singleinstitution studies also include a number of different lymphoma subtypes, making conclusions regarding specific entities difficult to draw. Frequently, many patients have undergone radiotherapy, prior autologous transplantation, or even prior allogeneic transplantation.
Small series have served as the foundation for more detailed and systematic studies of nonmyeloablative transplantation, yet the largest series to date remain in abstract form with limited data and short follow-up. Registry analyses and retrospective single-center experiences are subject to referral bias, physician preference, and variability in patient selection and standards of supportive care, reinforcing the need for randomized, prospective trials. Despite these limitations, results from studies examining the role of nonmyeloablative transplantation in the treatment of several lymphoma histologies are encouraging and are summarized below and in Table 4 .
Chronic lymphocytic leukemia
An increasing amount of data has indicated that allogeneic transplantation is a potentially curative approach Graft-versus-lymphoma effect BW Butcher and RH Collins for chronic lymphocytic leukemia (CLL), 54 although the substantial treatment-related mortality associated with myeloablative therapy has restricted its broad application. Several recent studies of nonmyeloablative transplantation for CLL have demonstrated significantly reduced morbidity and mortality with preservation of durable clinical and molecular remissions. 55 In four of the largest series to date, 2-year overall survival for recipients of nonmyeloablative allografts ranges from 68 to 80%, with 40-71% of patients achieving complete remissions. These data are comparable to those reported in a number of studies investigating myeloablative allogeneic transplantation. [56] [57] [58] Since CLL is primarily a disease of older patients, many of whom cannot tolerate myeloablative preparative regimens, nonmyeloablative transplantation has considerable promise given its reduced toxicity, apparent efficacy, and potential for cure.
Follicular and low-grade lymphoma
Conventional allogeneic transplantation for low-grade lymphoma is associated with a 40% chance of long-term disease-free survival but has a high rate of treatmentrelated mortality. In a study of 20 patients with follicular or small-cell lymphocytic lymphoma undergoing nonmyeloablative allogeneic transplantation with or without rituximab, all patients achieved complete remission, and none had relapsed after a median follow-up of 21 months. 59 Overall and progression-free survival at 2 years were both 84%, but most patients had nonbulky chemosensitive disease, and follow-up was relatively short for a disease with a propensity for late relapse. In the context of larger studies of nonmyeloablative transplantation, where data for individual subjects are often difficult to obtain, follicular lymphomas have generally high complete response (CR) rates, often approaching 100%. Although the number of patients with indolent lymphoma in these studies is small and follow-up is often comparatively short, these data are promising. Prospective trials with long-term follow-up are necessary to define the role of nonmyeloablative allogeneic transplantation in the treatment of low-grade disease.
Mantle cell lymphoma
Evidence of a graft-versus-mantle cell lymphoma (MCL) effect has been reported in several patients following myeloablative allografting. [60] [61] [62] Khouri et al 63 studied the efficacy of nonmyeloablative transplantation in 18 MCL patients with progressive or recurrent disease after conventional chemotherapy or autologous transplantation. Following conditioning with fludarabine-containing regimens, donor cell engraftment occurred in all patients, mortality at 100 days was 0, and 94% of patients achieved CR. At a median follow-up period of 26 months, three patients had relapsed, although one was reinduced into CR with DLI. A contemporaneous study by Dasgupta et al 64 had less promising results, with only 48% of patients alive and disease-free at a median of 21.5 months post transplant. Given that MCL is incurable with conventional chemotherapy and that no plateau exists in the survival curve following autologous transplantation, these preliminary results are encouraging.
Aggressive lymphoma (including diffuse large B-cell lymphoma and transformed low-grade lymphoma)
To date, no large series investigating the efficacy of nonmyeloablative transplantation specifically in diffuse large cell or transformed low-grade lymphoma exist, and individual cases must be drawn from larger reports that include various histologies. Complete remission rates in these reports range from 50 to 100%, although the majority has fewer than five patients, many of whom received conditioning regimens of differing intensity. Escalo´n et al 65 described a cohort of 10 patients with diffuse large-cell lymphoma, who had failed prior autologous transplantation despite having chemosensitive or stable disease. Following nonmyeloablative allografting, all patients achieved durable complete remissions, with only one death, which was secondary to pulmonary Aspergillus infection at 10.5 months post transplantation.
In another study, 18 patients with aggressive lymphoma were treated with a debulking autograft followed by a nonmyeloablative allograft. At a median follow-up of 22 months, eight patients were alive in complete remission, The number of patients refers to only those patients in the study who underwent nonmyeloablative stem cell transplantation, although, in some instances, a larger number of patients was included in the report (including recipients of other therapies). Accompanying actuarial and transplant-related morbidity and mortality statistics also refer only to those patients in the reports who received nonmyeloablative stem cell transplantation.
b Studies including several lymphoma histologies often present follow-up data and actuarial statistics based on the total study population rather than by unique histologies. Accordingly, data marked b is inclusive of all patients in the study and not just those with the specific histology listed in the table. CR ¼ complete response; PR ¼ partial response; PFS ¼ progression-free survival; EFS ¼ event-free survival; OS ¼ overall survival; GVHD ¼ graft-versus-host disease; TRM ¼ treatment-related mortality; NRM ¼ non-relapse mortality; CLL ¼ chronic lymphocytic leukemia; DLI ¼ donor leukocyte infusion; NST ¼ nonmyeloablative stem cell transplantation; ASCT ¼ autologous stem cell transplantation; IS ¼ immunosuppression; NS, not stated.
with the best results occurring in patients with full donor chimerism and acute or chronic GVHD. 66 In a similar study of 62 aggressive histology lymphoma patients treated with a nonmyeloablative allograft, 1-year overall and progression-free survival rates were 52 and 32%, respectively. 67 In all, 47% of patients progressed at 1 year, and in light of this marked disease progression, the authors suggest that additional strategies may be required to control aggressive histology disease. Despite this, the subsequent response of some patients to DLI and the absence of relapse in patients receiving matched unrelated donor allografts lend credence to the existence of a graftversus-lymphoma effect for aggressive histology disease.
Hodgkin's disease
Myeloablative allogeneic transplantation results in significantly lower relapse rates than autologous transplantation in the treatment of HD, but treatment-related mortality approaches 50% in some series. Although retrospective studies of nonmyeloablative transplantation for HD often include few patients and have short follow-up, they suggest that even in heavily pretreated patients with refractory disease, sustained complete remissions are achievable with low treatment mortality rates. In these studies, complete response rates have ranged from 25 to 100%, and responses are highly correlated with the development of GVHD. A retrospective analysis of 99 patients receiving nonmyeloablative allografts for relapsed or refractory HD showed a complete remission rate of 42%, comparable to the control group of 154 patients receiving myeloablative allografts. 68 In a similar study of 41 multiply relapsed and refractory Hodgkin's lymphoma patients conditioned with fludarabine, alemtuzumab (Campath-1H), and melphalan, projected 4-year overall and progression-free survival were 63 and 34%, respectively, with a treatment-related mortality of 20%. 69 Survival statistics were even more encouraging in the small subset of patients who had not undergone prior autologous transplantation. Thus, nonmyeloablative allogeneic transplantation remains an attractive strategy for the treatment of HD, particularly in high-risk patients who have already failed autologous transplantation. 70 
Other histologies
Nonmyeloablative stem cell transplantation has also been studied in less common lymphoma histologies. Corradini and colleagues treated 17 patients with resistant or relapsed peripheral T-cell lymphomas with a conditioning regimen of thiotepa, fludarabine, and cyclophosphamide followed by allogeneic transplantation. After a median follow-up of 28 months, 71% of patients had achieved and maintained CR, with estimated 3-year overall and progression-free survival rates of 81 and 64%, respectively. 71 Durable complete remissions have also been observed in small series of patients with Sezary syndrome and mycosis fungoides, 72 marginal zone lymphoma, [73] [74] [75] immunocytoma, 76 lymphoplasmacytic lymphoma, 74 anaplastic large-cell lymphoma, lymphoblastic lymphoma, 77 Burkitt's lymphoma, 78 and Waldenstro¨m's macroglobulinemia. 79 
Role of prophylactic DLI in nonmyeloablative transplantation
In many studies of nonmyeloablative transplantation, DLIs are selectively given to patients for mixed chimerism, disease progression, and/or relapse following transplantation. Their role in augmenting the putative graft-versuslymphoma effect remains elusive, 80 however, given the often incomplete nature of data reporting in the literature. A retrospective analysis by Bethge et al 81 examined the responses of 53 patients with various hematologic malignancies to DLI following nonmyeloablative allogeneic transplantation. Of the 48 patients receiving DLI for residual or progressive disease, seven achieved CR and five achieved partial response (PR), yielding an overall response rate of 25%. Both the degree of chimerism and the development of GVHD were positively correlated with disease response. Although the responses of lymphoma patients cannot be distinguished from those with other malignancies, the authors conclude that, in general, DLI administration is a minimally toxic and efficacious treatment for some patients with persistent or progressive disease following unsuccessful nonmyeloablative transplantation.
Peggs et al 82 similarly addressed the role of doseescalated DLIs following nonmyeloablative transplantation in 46 lymphoma and myeloma patients with mixed chimerism (n ¼ 14), residual disease (n ¼ 13), or disease progression/relapse (n ¼ 19). In all, 70% of patients with HD achieved CR or PR, and response was significantly correlated with the development of GVHD. Of the five evaluable patients with non-Hodgkin's lymphoma (n ¼ 4) or CLL (n ¼ 1), four achieved CR or PR, with some responses occurring in the absence of GVHD. A third study examining the efficacy of prophylactic DLIs in 42 patients with advanced hematologic malignancies similarly concluded that they could convert patients to full donor chimerism and effect sustained remissions in some patients with chemoresistant disease. 83 
Failure of prior autografts
Despite improved outcomes in lymphoma patients treated with myeloablative therapy and autologous transplantation, disease progression remains the principle cause of treatment failure. 84 Indeed, relapse after autografting confers a median survival of 10.5 and 3 months for patients with HD and non-Hodgkin's lymphoma, respectively. 85 Accordingly, one of the most compelling lines of evidence for the existence of a graft-versus-lymphoma effect is the success of allogeneic transplantation following failed autologous transplantation in patients with refractory disease. Myeloablative conditioning with allogeneic transplantation is generally precluded by high treatment-related mortality, and accordingly, several studies have investigated the efficacy of nonmyeloablative transplantation in this setting. [86] [87] [88] [89] Escalo´n and colleagues studied 20 patients with recurrent non-Hodgkin's lymphoma after autologous transplantation, who underwent nonmyeloablative transplantation. Following fludarabine-based conditioning, all patients engrafted, and 19 (95%) achieved complete remission. The remaining patient had progressive disease at day þ 115, was treated with DLI, developed GVHD, and achieved a complete remission at day þ 220. The estimated 3-year progression-free survival was 95%, although all patients included in the study had either chemosensitive or low-bulk stable disease at the time of relapse. 65 Branson et al 90 similarly studied the efficacy of nonmyeloablative transplantation in 38 high-risk patients with relapsed or refractory lymphoid malignancies following autologous transplantation. Following conditioning with alemtuzumab, fludarabine, and melphalan, 97% of patients engrafted, and no grade III/IV GVHD was observed. Of the 35 assessable patients, 14 received DLI for progressive or relapsed disease after transplantation; two patients with HD also received additional chemotherapy because of high tumor burden. Given the collectively poor prognosis of the patient cohort, the response rates were encouraging, and overall and progression-free survival at 14 months were 53 and 50%, respectively. Nevertheless, a significant number of postprocedure relapses and a progression-free survival curve without a plateau necessitate longer follow-up of this patient cohort. Thus, conflicting data exist regarding the efficacy of nonmyeloablative transplantation following failed autologous transplantation, with more encouraging results seen in patients with chemosensitive disease and minimal tumor burden.
The role of GVHD
Approximately two-thirds of patients receiving DLI for hematologic malignancies will develop acute and chronic GVHD. Reviews of North American and European databases have suggested a strong temporal association and statistical correlation between the development of GVHD and the induction of an antileukemic response. Addressing the association of GVHD and a graft-versuslymphoma response requires the answers to two fundamental questions: of complete responders, how many developed acute GVHD and chronic GVHD, and of patients who did not develop GVHD, how many were complete responders. Unfortunately, the incomplete nature of data reporting in the literature is often not amenable to such an analysis.
Mohty et al 91 investigated the correlation between the development of GVHD and disease relapse in 101 high-risk patients with a variety of diagnoses following nonmyeloablative transplantation with fludarabine, busulfan, and antithymocyte globulin. The cumulative incidence of disease progression or relapse at 1 year was 30% in patients who developed GVHD (n ¼ 69) and 55% in those who did not (n ¼ 31; P ¼ 0.02), suggesting a durable graftversus-tumor effect closely associated with the development of GVHD. Similarly, a retrospective analysis of 124 transplant recipients for non-Hodgkin's lymphoma in Japan showed that the development of grade II-IV GVHD was strongly associated with a lower incidence of disease progression after transplantation (5.8 vs 29.7%, P ¼ 0.0054). 92 Despite this association, the possibility of disease response in the absence of clinical GVHD and the significant morbidity and mortality of GVHD 93 have resulted in a number of approaches to minimize its incidence or severity following DLI. These include delayed administration of DLI, 94 ex vivo insertion of suicide genes into donor T cells prior to DLI, 95 and selective depletion of specific lymphocyte subpopulations prior to DLI. 96 Thus, despite the frequent correlation between the incidence of GVHD and antitumor activity, the development of GVHD is neither necessary nor sufficient to evoke a graft-versuslymphoma response. More complete data reporting is essential to address this question statistically.
Current clinical management
The current data collectively suggest a significant graftversus-lymphoma effect that can be harnessed clinically, yet its applicability appears dependent on disease histology and individual patient and disease characteristics. Moreover, the role of clinical approaches that attempt to harness the graft-versus-lymphoma effect, such as nonmyeloablative transplantation, have yet to be compared with other clinical approaches in optimal fashion. The field offers significant opportunity for clinical research (discussed below), and we strongly encourage participation in clinical trials when possible. Nevertheless, the physician must make clinical decisions regarding management of lymphoma patients in the present tempered with the understanding that the existing data are far from perfect. We offer here suggestions about the current use of DLI and allogeneic transplantation for the treatment of lymphoma patients.
Donor leukocyte infusions
Patients with persistent or relapsed disease following allogeneic stem cell transplantation may be suitable candidates for DLI. Diseases that seem most responsive to DLI include CLL, follicular lymphoma, and MCL. Patients with slowly growing, less bulky disease may be treated with DLI alone without the need for pre-DLI treatment. Lower T-cell doses, such as 10 7 CD3 þ cells/kg, might be used first, with higher doses, such as 10 8 CD3 þ cells/kg, reserved for patients who have failed to respond after several weeks of observation. Some studies suggest lower T-cell doses might be more likely to mediate disease response (at least in CML) without causing GVHD. 97 Patients with more aggressive disease should likely be treated with debulking therapy prior to DLI administration and higher T-cell doses initially. Debulking therapy might include standard antilymphoma chemotherapeutic agents, rituximab, or radio-labeled monoclonal antibodies. Alemtuzumab should be avoided in this circumstance given its anti-T-cell activity.
In the setting of nonmyeloablative transplantation, DLI administration depends largely on the GVHD prophylaxis used following transplantation. In approaches using alemtuzumab, DLI, given several weeks after transplantation to ensure clearance of Campath, is much more likely to be required to achieve optimal disease control. Approaches using tacrolimus/methotrexate or cyclosporin/mycophenolate, in contrast, are less likely to require subsequent DLI, as delayed disease responses often occur after discontinuation of these agents, often in association with development of chronic GVHD. 35 
Allografting
Chronic lymphocytic leukemia. Allografting should be considered in CLL patients with a poor prognosis as defined by clinical characteristics and cytogenetic abnormalities. We generally favor myeloablative regimens in younger patients at this point because we believe that efficacy data for nonmyeloablative transplants are too preliminary to allow their general adoption; moreover, advances in supportive care seem to have lessened treatment-related mortality of myeloablative regimens for otherwise healthy younger patients. For older patients and those with significant comorbidities, one of several nonmyeloablative strategies might be employed with some expectation of success (see Table 4 ).
Follicular lymphoma. Allografting should be reserved for patients with poor prognoses and more advanced disease, such as first relapse and beyond. (In addition, one should consider autografting for patients in second remission given recent randomized data. 98 ) Again, we recommend myeloablative approaches for younger, healthier patients, and nonmyeloablative approaches, many of which appear promising, for older patients and those with significant comorbidities (see Table 4 ).
Mantle cell lymphoma. The role of autografting vs allografting in first remission disease is not clear based on current data, yet more advanced disease, such as disease in second remission, is very unlikely to be cured with autografting. We believe that the current data suggest utility in this setting for allografting and would recommend consideration of this approach, with myeloablative regimens in younger, healthier patients, and nonmyeloablative regimens in older patients and those with significant comorbidities.
Diffuse large B-cell lymphoma. Randomized data support the use of autografting in relapsed chemosensitive disease and first remission poor-risk disease. 99, 100 Allografting, in contrast, might be considered in the settings of primary refractory disease, relapse-refractory disease, or relapsed disease following autologous transplantation, although the data supporting a graft-versus-lymphoma effect are not as compelling with this histology. Regarding the use of nonmyeloablative transplantation in patients having relapsed after autografts, we emphasize that the group of patients supported by Escalo´n et al 65 was a highly selected group with fairly early relapses.
Hodgkin's Disease. Randomized data support the use of autografting in relapsed disease, 101 although allografting may be considered in poor-risk patients, including those with chemotherapy refractory disease. The study by Peggs et al is encouraging in that it shows excellent disease-free survival at 4 years in patients treated with fludarabine, melphalan, and alemtuzumab, yet this study currently remains in abstract form.
Other histologies. Data for other histologies are too limited to allow even tentative conclusions, although some data, such as those in peripheral T-cell lymphoma, are intriguing. 71 The reader is referred to Table 4 for data that might be helpful in decision-making for individual patients.
Other approaches. As transplanters, we are sometimes guilty of thinking that a transplant, in one form or another, is the only suitable strategy for our patients, when other approaches, including palliative chemotherapy, are often more appropriate. Indeed, the authors have several patients who have been palliated for months to years with intermittent courses of well-tolerated oral chemotherapy. Other potential approaches include rituximab, radio-labeled antibodies, or experimental agents including bortezomib, which shows activity in MCL. Lastly, many patients are best served by a purely palliative approach that ensures that physical, emotional, and spiritual concerns are met.
Mechanism of the graft-versus-lymphoma effect
The mechanism of the graft-versus-lymphoma effect remains unknown but is thought to be principally mediated by T cells and possibly NK cells. The putative target antigens of T cells can be divided into three categories: alloantigens that are broadly expressed on both malignant cells and normal epithelial cells; alloantigens that are expressed on both malignant cells and normal hematopoietic cells; and antigens that are expressed solely by malignant cells, including peptides derived from tumor-specific proteins, viral proteins, or overexpressed differentiation antigens. Alloantigens expressed on both malignant and normal epithelial cells would be expected to elicit a graftversus-lymphoma effect in close association with clinical GVHD, while alloantigens expressed on both malignant and normal hematopoietic cells, despite being alloreactive, might elicit a graft-versus-lymphoma reaction without causing clinical GVHD. The frequent association between lymphoma responses and GVHD raises the possibility that alloantigens are the target of the graft-versus-lymphoma effect, although this observation does not exclude the possibility of lymphoma-specific T-cell clones arising alongside alloreactive T-cell clones. Lymphoma responses observed in the absence of GVHD suggest the presence of either tumor-specific T-cell clones or alloreactive clones that are reactive only with hematopoietic tissue-restricted alloantigens. This cannot, however, rule out the presence of a broadly alloreactive T-cell clone that is not present in sufficient quantity to cause clinically apparent GVHD.
The definitive role of GVHD in the context of a human graft-versus-lymphoma effect is not yet certain, but in some murine models, the two phenomena can be distinctly separated. 102 Pelot and colleagues showed that administration of nontolerant donor cells as early as 5 weeks post transplant leads to full or nearly full donor chimerism in 80% of recipients without concomitant GVHD. This suggests that induction of mixed chimerism with nonmyeloablative conditioning effectively sets the stage for DLI to combat chronic hematologic malignancies without causing clinically significant GVHD. Preliminary data from the same group strongly suggest that establishment of mixed chimerism and sufficient time for host recovery after conditioning are associated with decreased incidence of GVHD in humans. A similar strategy has had modest success in canine models. [103] [104] [105] Although animal models are valuable, the use of DLI and nonmyeloablative transplantation in human subjects provides the unique opportunity to study the mechanism of the graft-versus-lymphoma effect during its evolution. For example, Marijt and colleagues have suggested that the hematopoiesis-restricted minor compatibility antigens (mHAgs) HA-1 and HA-2 expressed on the surface of malignant cells serve as target antigens for alloreactive donor T cells. Three mHAg HA-1-and/or HA-2-positive patients with relapsed chronic phase CML (n ¼ 2) or multiple myeloma (n ¼ 1) after allogeneic transplantation were treated with DLI from their respective mHAg HA-1-and/or HA-2-negative donors, and HLA-A2/HA-1 and HA-2 peptide tetrameric complexes were used to monitor anti-mHAg T cells. 106 The emergence of tetramer-positive CD8 þ T cells 5-7 weeks after DLI was followed immediately by complete remission of disease and restoration of 100% donor chimerism in each patient. Moreover, tetramer-positive cytotoxic T cells arising during the clinical response specifically recognized HA-1-and HA-2-expressing malignant cells and inhibited the growth of leukemic precursor cells in vitro. The authors caution, however, that additional activated T-cell clones were present and may have contributed to the graft-versustumor effect. Takahashi et al have recently shown that this observation is not limited to hematologic malignancies. In some cases, minor histocompatibility antigen-specific T cells mediate pronounced graft-versus-tumor effects in patients with cytokine-refractory metastatic renal cell carcinoma following nonmyeloablative transplantation. 107 Bellucci et al 108 by screening a myeloma cDNA expression library with serum from four patients achieving complete response after DLI, identified antibodies to 13 target antigens of the graft-versus-myeloma response, five of which were present in more than one patient. These proteins were reactive with post-DLI serum but not with pre-DLI and pre-BMT serum and only minimally reactive with the sera of 20 healthy donors and 20 patients with chronic GVHD. The development of a sustained, high-titer antibody response to a number of myeloma-associated antigens, whose expression is significantly higher than in normal plasma cells, highlights their immunogenicity and identifies them as targets for further immunologic interventions. A similar strategy might be applied to lymphoma patients having undergone DLI to identify potential targets of a graft-versus-lymphoma reaction.
As highlighted above, most mechanistic studies of graftversus-tumor responses focus on effector cells and the putative target antigens rather than characteristics of target tumor cells that determine susceptibility to immune effector mechanisms. To be an appropriate target of an immune response, a tumor cell must: process and present antigen on the cellular surface in the context of an HLA molecule, express appropriate adhesion molecules to facilitate interaction with effector cells, and express functional apoptotic machinery. The tumor antigen also must be presented along with a costimulus, either by the tumor cell itself, or by host or donor antigen-presenting cells that have taken up tumor antigen. The tumor cell can escape death by subverting any of these key elements of the immune response. 109, 110 In addition, recent studies have suggested that the relevant target cell population of a tumor may be the small subset of cells that serve as tumor stem cells. 111, 112 Studies of leukemia have suggested that tumor stem cells differ from other tumor cells and from their normal tissue stem cell counterparts; only the tumor stem cells are capable of transmitting cancer when transplanted into irradiated animals. Thus, one might envision future studies involving isolation of tumor stem cells and investigation of the characteristics that either promote or limit susceptibility to immune attack.
Conclusions and future considerations
Although it is important to appreciate the difficulties in interpreting the literature and to realize that current data must be considered preliminary, we believe that the literature strongly suggests the existence of a graft-versuslymphoma effect. Additional research is essential to better define the effect, and this includes:
1. Retrospective registry analyses. Large-scale analyses of DLI and nonmyeloablative transplantation data will provide further insight into which diseases are vulnerable to the graft-versus-lymphoma effect. As much as possible, such studies should specifically address alternative explanations for disease response, including pre-DLI and post-DLI therapies, which may have intrinsic antitumor activity. The nonmyeloablative stem cell transplantation patients of greatest interest are those treated with less intensive preparative regimens, such as fludarabine and low-dose cyclophosphamide or fludarabine and total body irradiation, as prolonged responses are less likely to be explained by the chemotherapy than by graft-versus-lymphoma activity. 2. Prospective phase II studies. Longer follow-up of current studies and additional, larger scale multicenter trials will grant further insight into long-term disease activity and regimen toxicity of nonmyeloablative transplantation, laying the groundwork for prospective comparative trials. Smaller scale phase II studies may investigate the efficacy of variations to current nonmyeloablative regimens, such as the incorporation of monoclonal antibodies or radio-labeled antibodies. 3. Prospective randomized studies. Current data are sufficient to allow design of prospective, randomized trials comparing nonmyeloablative transplantation to autologous transplantation or conventional therapy in a variety of settings, including poor-prognosis CLL, follicular lymphoma in second remission, and MCL in first or subsequent remission. Randomized studies may also allow comparison of various nonmyeloablative transplantation strategies, including less intensive vs more intensive nonmyeloablative regimens and nonmyeloablative transplantation with or without alemtuzumab. 4 . Studies of graft-versus-lymphoma mechanisms. The above clinical studies will better define the role of nonmyeloablative transplantation in the management of various lymphoma histologies. Although a significant percentage of responders will certainly suffer from severe chronic GVHD, the purposeful induction of debilitating chronic GVHD has limited appeal as longterm therapy. Thus, it is critical that careful investigation of graft-versus-lymphoma mechanisms accompany clinical trials of DLI and nonmyeloablative transplantation. Again, we cannot overemphasize the unique opportunity that these therapies offer to study powerful antitumor mechanisms during their evolution. In addition, we stress the importance of intensively studying the characteristics of target tumor cells in an effort to elucidate factors that influence sensitivity to destruction by immune-mediated mechanisms. 5. Potential clinical approaches based on improved preclinical understanding of graft-versus-lymphoma. A variety of approaches are under investigation that seek to simultaneously enhance graft-versus-tumor activity and limit development of GVHD. These approaches include: delayed administration of DLI, 97 selective depletion of CD8 þ T cells 113 or alloreactive T cells from a donor T-cell inoculum, 114 ex vivo insertion of suicide genes into donor T cells prior to DLI, 115 use of antigen-specific T cells lines and clones, 116 and immunization of the donor with tumor-specific protein before DLI. 117 One can imagine that basic insights into graft-versuslymphoma mechanisms might provide the rationale to emphasize one or another of these approaches in future clinical studies.
We are optimistic that such mechanistic and clinical studies will allow the graft-versus-lymphoma effect to realize its full potential, which at this point seems quite promising.
